Clinical trial
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung…
NCT00232206 · Providence Health & Services, Other · Terminated
Key facts
| NCT number | NCT00232206 |
|---|---|
| Title | Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer |
| Official title | A Phase II Study of Cisplatin Plus Docetaxel as Neoadjuvant Therapy for Stages IB Through Selected IIIA NSCLC |
| Lead sponsor | Providence Health & Services, Other |
| Collaborators | Providence Cancer Center, Earle A. Chiles Research Institute Sanofi Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Neoadjuvant Therapy with Cisplatin Plus Docetaxel |
| Enrollment | 40 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Oct 4, 2005 |
| Last update posted | May 18, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: